Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in...

HUTCHMED (China) Ltd (HCM) reports robust China product sales and global expansion, while advancing its novel ATTC pipeline and maintaining a profitable outlook.

HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported results. The company maintained its full-year oncology revenue guidance of $330 million to $415 milli

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. HUTCHMED (China) Limited (NASDAQ:HCM) is one of the most undervalued pharma stocks. TheFly reported on May 28 that Morgan Stanley upgraded HCM to Equal Weight from Underweight and set a new price target of $13.60, slightly below the prior $13.75 […]

HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at the 30th Deutsche Bank deposit receipts virtual investor conference. 2025 financial performance and l

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Despite challenges, HUTCHMED (China) Ltd (HCM) reports robust sales growth and outlines ambitious oncology revenue targets for 2026.

BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print “offered some positive steps forward after a weaker 1H25.” Directional commentary about fruquintinib indication expansion in 2026 and increasing the number of Fruzaqla markets bolsters the firm’s confidence that Hutchmed can meet their 2026 guidance for Oncology/Immunology, the analyst tells investors.Claim 70% Off TipRanks Premiu

HUTCHMED (NASDAQ:HCM) management used its 2025 annual results call to highlight growth in global sales for FRUZAQLA, a rebound in China market performance in the second half, and increasing investment behind its ATTC (antibody-targeted therapy conjugate) platform as it advances multiple assets into

We came across a bullish thesis on Paycom Software, Inc. on The Wealth Dynasty Report’s Substack. In this article, we will summarize the bulls’ thesis on PAYC. Paycom Software, Inc.’s share was trading at $134.75 as of January 30th. PAYC’s trailing and forward P/E were 16.69 and 13.16 respectively according to Yahoo Finance. Paycom Software, Inc. provides a […]